Colchicine as a Potential Anti-Inflammatory Strategy for Aortic Aneurysm

experienced a myocardial infarction or patients with chronic coronary disease, respectively. 3,4In addition to its benefits, colchicine is a viable option because of its cost-effectiveness and safety in low-dose usage.Based on these low-dose colchicine was approved in 2023 by the U.S. Food and Drug Administration (FDA) for the reduction of cardiovascular risk.Colchicine exerts multiple anti-inflammatory effects mainly by inhibiting microtubule polymerization.In particular, colchicine is concentrated in neutrophils and impairs their function by disrupting microtubules. 2Neutrophils are the primary target of colchicine, which inhibits key functions,